Sucampo Pharmaceuticals and development and commercialization partner Takeda Pharmaceuticals have begun global pivotal Phase III program to study lubiprostone in pediatric functional constipation. Functional constipation is a very common gastrointestinal complaint in children and is on the rise. An analysis of longitudinal data in the U.S. showed a nearly fourfold increase in rates of constipation over the last decade. Lubiprostone is the world’s first chloride channel activator that incr...